Product
Treatment as Usual
Aliases
Treatment as Usual (TAU)
5 clinical trials
11 indications
Indication
Methamphetamine AbuseIndication
Methamphetamine dependenceIndication
Substance Use DisorderIndication
SubstanceIndication
Bipolar disorderIndication
Opioid Use DisorderIndication
ModerateIndication
SevereIndication
Idiopathic Pulmonary FibrosisIndication
Acute Fatal FormIndication
Bipolar DisorderClinical trial
Addition of High Dose Stimulant and Engagement-focused Contingency Management (CM), Alone and in Combination, to Treatment as Usual (TAU) for the Management of Methamphetamine (MA) Use Disorder (ASCME): a Canadian Multi-centre, RCTStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Randomized Controlled Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar DepressionStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Exemplar Hospital Initiation Trial to Enhance Treatment Engagement - Comparative Effectiveness Trial of Extended Release Buprenorphine Versus Treatment as Usual for Hospitalized Patients With Opioid Use DisorderStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Study of Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF)Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Culturally Adapted Psychoeducation (CaPE) for Bipolar Disorders in Nigeria: A Pilot Randomised Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2024-06-30